Tredence Acquires KMK Consulting to Accelerate Healthcare and Life Sciences Growth

Tredence, a leading provider of AI and data science solutions, has announced its acquisition of KMK Consulting, a specialized analytics and consulting firm with a strong focus on the Life Sciences and Biopharma sectors. The deal, which was finalized on June 22, 2026, involves an undisclosed amount and marks a strategic move for Tredence as it aims to position Healthcare & Life Sciences (HLS) as a significant growth area, targeting 25% of its overall revenue by 2028.

KMK Consulting, headquartered in Morris Plains, New Jersey, has established itself as a key player in the Life Sciences industry, working with eight of the world's top ten pharmaceutical companies. With over two decades of experience, KMK specializes in commercial analytics, real-world evidence (RWE), and market research. This acquisition not only enhances Tredence's capabilities in these areas but also integrates KMK's deep domain expertise with Tredence's advanced AI technologies, creating a unique set of offerings tailored for Life Sciences clients.

The strategic rationale behind this acquisition lies in the rapidly evolving landscape of the pharmaceutical industry, where AI adoption is accelerating. The global market for AI in Life Sciences is projected to reach $69.3 billion by 2031. By combining KMK's expertise with Tredence's capabilities in applied AI and data engineering, the partnership is expected to streamline processes across the entire pharmaceutical value chain, from research and development to commercial launch. This alignment is particularly relevant as pharmaceutical companies seek to leverage data at scale to unlock new value creation opportunities.

Additionally, the acquisition strengthens Tredence's position within the Veeva ecosystem, a leading cloud-based CRM and data platform used by a significant majority of pharmaceutical companies for managing commercial operations and medical engagements. As the demand for sophisticated AI solutions grows, Tredence's enhanced capabilities in HLS will allow it to capitalize on this trend, positioning the company as a vital partner in the ongoing digital transformation within the sector.

Overall, this acquisition signals a broader trend in the Healthcare and Life Sciences sectors, where companies are increasingly recognizing the importance of combining deep domain expertise with advanced technology solutions. Tredence's strategic move to integrate KMK Consulting is expected to not only drive its growth in HLS but also contribute to the evolution of AI applications in the pharmaceutical industry, ultimately enhancing the value delivered to clients and stakeholders. As the market continues to evolve, Tredence is well-positioned to play a pivotal role in shaping the future of AI in Life Sciences.